The Diagnostic and Treatment Challenges of Concomitant Mantle Cell Lymphoma and IgM Myeloma

Dhairya Gor; Rohan Mehta; David Greenberg; Evgeniya Angelova

doi:10.12890/2022_003463

The Diagnostic and Treatment Challenges of Concomitant Mantle Cell Lymphoma and IgM Myeloma

Eur J Case Rep Intern Med. 2022 Jul 7;9(7):003463. doi: 10.12890/2022_003463. eCollection 2022.

Authors

Dhairya Gor¹, Rohan Mehta², David Greenberg², Evgeniya Angelova³

Affiliations

¹ Internal Medicine Department, Jersey Shore Medical Center, Neptune, NJ, USA.
² Hematology Oncology Department, Jersey Shore Medical Center, Neptune, NJ, USA.
³ Pathology Department, Jersey Shore Medical Center, Neptune, NJ, USA.

Abstract

It is rare for IgM multiple myeloma (MM) and mantle cell lymphoma (MCL) to coexist. Furthermore, it is challenging to demonstrate if there are two distinct types of neoplasia or if plasma cell differentiation of MCL is present. We discuss the case of a patient concomitantly diagnosed with MCL and IgM MM, and the subsequent diagnostic and management difficulties, and the positive treatment outcome.

Learning points: Due to the rarity of simultaneous multiple myeloma (MM) and mantle cell lymphoma (MCL), it is challenging to investigate a possible association.This report will draw attention to the condition's rarity, diagnostic and treatment hurdles, and hopefully inspire future research into therapeutic alternatives.Several recent developments indicate a bright future for treating refractory malignancies such as MM and MCL, such as the advent of chimeric antigen receptor T-cell (CAR T-cell) therapy.

Keywords: CAR T-cell therapy; IgM multiple myeloma; mantle cell lymphoma.